Isabel Coutinho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabel Coutinho has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Lucília Saraiva
LAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal
5 shared publications - Jorge Gonçalves
Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
3 shared publications - Luke A. Selth
Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Bedford Park, SA, 5042, Australia.
3 shared publications - Wayne D. Tilley
Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia
3 shared publications - Clara Pereira
I3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
2 shared publications Gil Pereira
2 shared publications
Latest Publications
- 1 July 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (13) , 3417-3430
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer
Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer is an important mechanism driving disease progression and therapy resistance. Using a novel proteomic technique, we identified a new AR coregulator, the transcription factor Grainyhead-like 2 (GRHL2), and demonstrated its essential role in the oncogenic AR signaling axis. GRHL2 colocalized with AR in prostate tumors and was frequently amplified and upregulated in prostate cancer. Importantly, GRHL2 maintained AR expression in multiple prostate cancer model systems, was required for cell proliferation, enhanced AR's transcriptional activity, and colocated with AR at specific sites on chromatin to regulate genes relevant to disease progression. GRHL2 is itself an AR-regulated gene, creating a positive feedback loop between the two factors. The link between GRHL2 and AR also applied to constitutively active truncated AR variants (ARV), as GRHL2 interacted with and regulated ARVs and vice versa. These oncogenic functions of GRHL2 were counterbalanced by its ability to suppress epithelial–mesenchymal transition and cell invasion. Mechanistic evidence suggested that AR assisted GRHL2 in maintaining the epithelial phenotype. In summary, this study has identified a new AR coregulator with a multifaceted role in prostate cancer, functioning as an enhancer of the oncogenic AR signaling pathway but also as a suppressor of metastasis-related phenotypes. Cancer Res; 77(13); 3417–30. ©2017 AACR.
- 1 July 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (13) , 3417-3430
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer
Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer is an important mechanism driving disease progression and therapy resistance. Using a novel proteomic technique, we identified a new AR coregulator, the transcription factor Grainyhead-like 2 (GRHL2), and demonstrated its essential role in the oncogenic AR signaling axis. GRHL2 colocalized with AR in prostate tumors and was frequently amplified and upregulated in prostate cancer. Importantly, GRHL2 maintained AR expression in multiple prostate cancer model systems, was required for cell proliferation, enhanced AR's transcriptional activity, and colocated with AR at specific sites on chromatin to regulate genes relevant to disease progression. GRHL2 is itself an AR-regulated gene, creating a positive feedback loop between the two factors. The link between GRHL2 and AR also applied to constitutively active truncated AR variants (ARV), as GRHL2 interacted with and regulated ARVs and vice versa. These oncogenic functions of GRHL2 were counterbalanced by its ability to suppress epithelial–mesenchymal transition and cell invasion. Mechanistic evidence suggested that AR assisted GRHL2 in maintaining the epithelial phenotype. In summary, this study has identified a new AR coregulator with a multifaceted role in prostate cancer, functioning as an enhancer of the oncogenic AR signaling pathway but also as a suppressor of metastasis-related phenotypes. Cancer Res; 77(13); 3417–30. ©2017 AACR.
- 1 December 2016
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 23 (12) , T179-T197
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC), which arises after failure of androgen deprivation therapy (ADT). Persistent AR activity in spite of ADT and the second-generation AR-targeting agents enzalutamide and abiraterone is achieved in many cases by direct alterations to the AR signaling axis. Herein, we provide a detailed description of how such alterations contribute to the development and progression of CRPC. Aspects of this broad and ever-evolving field specifically addressed in this review include: the etiology and significance of increased AR expression; the frequency and role of gain-of-function mutations in theARgene; the function of constitutively active, truncated forms of the AR termed AR variants and the clinical relevance of alterations to the activity and expression of AR coregulators. Additionally, we examine the novel therapeutic strategies to inhibit these classes of therapy resistance mechanisms, with an emphasis on emerging agents that act in a manner distinct from the current ligand-centric approaches. Throughout, we discuss how the central role of AR in prostate cancer and the constant evolution of the AR signaling axis during disease progression represent archetypes of two key concepts in oncology, oncogene addiction and therapy-mediated selection pressure.
- 1 December 2016
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 23 (12) , T179-T197
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC), which arises after failure of androgen deprivation therapy (ADT). Persistent AR activity in spite of ADT and the second-generation AR-targeting agents enzalutamide and abiraterone is achieved in many cases by direct alterations to the AR signaling axis. Herein, we provide a detailed description of how such alterations contribute to the development and progression of CRPC. Aspects of this broad and ever-evolving field specifically addressed in this review include: the etiology and significance of increased AR expression; the frequency and role of gain-of-function mutations in theARgene; the function of constitutively active, truncated forms of the AR termed AR variants and the clinical relevance of alterations to the activity and expression of AR coregulators. Additionally, we examine the novel therapeutic strategies to inhibit these classes of therapy resistance mechanisms, with an emphasis on emerging agents that act in a manner distinct from the current ligand-centric approaches. Throughout, we discuss how the central role of AR in prostate cancer and the constant evolution of the AR signaling axis during disease progression represent archetypes of two key concepts in oncology, oncogene addiction and therapy-mediated selection pressure.
- 6 June 2016
- Published by Springer Nature in Oncogene
- Vol. 36 (1) , 24-34
A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.
- 6 June 2016
- Published by Springer Nature in Oncogene
- Vol. 36 (1) , 24-34
A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.
- Open Access
- 7 December 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12) , e0144790
Correction: Modulating the Structure of EGFR with UV Light: New Possibilities in Cancer Therapy
- 7 December 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12) , e0144790
Open AccessCorrection: Modulating the Structure of EGFR with UV Light: New Possibilities in Cancer Therapy
- 1 April 2014
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 54, 8-16
Potential small-molecule activators of caspase-7 identified using yeast-based caspase-3 and -7 screening assays
- 1 April 2014
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 54, 8-16
Potential small-molecule activators of caspase-7 identified using yeast-based caspase-3 and -7 screening assays
- 1 April 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (17) , 2492-2500
Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Protein kinase C (PKC) is a family of serine/threonine kinases involved in the transduction of signals that control different cellular processes, such as cell death and proliferation. This family comprises at least 10 isoforms that regulate apoptosis in an isoformspecific manner. However, controversial data about the role of individual PKC isoforms in apoptosis regulation are frequently reported. The co-existence of several PKC isoforms in a same mammalian cell, the distinct expression profile of PKC isoforms in different cell types, and the different stimulus applied may explain such contradicting results. Therefore major advances in the understanding of the molecular mechanisms that regulate the function of PKC isoforms in apoptosis are still required. Yeast has proved to be a valuable research tool to investigate molecular aspects of apoptosis regulation. Additionally, the conservation in yeast of major functional and molecular properties of mammalian PKC isoforms favours the use of this simpler cell model to uncover relevant aspects of apoptosis regulation by this kinase family. In this review, we cover the current knowledge about the role of different PKC isoforms in apoptosis. Moreover, we discuss the contribution of yeast to unravel several controversial issues about apoptosis regulation by PKC isoforms. The exploitation of yeast cells expressing individual PKC isoforms towards the identification of isoform-specific PKC modulators is also discussed. The studies here summarised highlight that the yeast cell model system can provide valuable insights in the PKC research field.
- 1 April 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (17) , 2492-2500
Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Protein kinase C (PKC) is a family of serine/threonine kinases involved in the transduction of signals that control different cellular processes, such as cell death and proliferation. This family comprises at least 10 isoforms that regulate apoptosis in an isoformspecific manner. However, controversial data about the role of individual PKC isoforms in apoptosis regulation are frequently reported. The co-existence of several PKC isoforms in a same mammalian cell, the distinct expression profile of PKC isoforms in different cell types, and the different stimulus applied may explain such contradicting results. Therefore major advances in the understanding of the molecular mechanisms that regulate the function of PKC isoforms in apoptosis are still required. Yeast has proved to be a valuable research tool to investigate molecular aspects of apoptosis regulation. Additionally, the conservation in yeast of major functional and molecular properties of mammalian PKC isoforms favours the use of this simpler cell model to uncover relevant aspects of apoptosis regulation by this kinase family. In this review, we cover the current knowledge about the role of different PKC isoforms in apoptosis. Moreover, we discuss the contribution of yeast to unravel several controversial issues about apoptosis regulation by PKC isoforms. The exploitation of yeast cells expressing individual PKC isoforms towards the identification of isoform-specific PKC modulators is also discussed. The studies here summarised highlight that the yeast cell model system can provide valuable insights in the PKC research field.
- 1 May 2011
- Published by Elsevier in Experimental Cell Research
- Vol. 317 (8) , 1147-1158
Distinct regulation of p53-mediated apoptosis by protein kinase Cα, δ, ε and ζ: Evidence in yeast for transcription-dependent and -independent p53 apoptotic mechanisms
- 1 May 2011
- Published by Elsevier in Experimental Cell Research
- Vol. 317 (8) , 1147-1158
Distinct regulation of p53-mediated apoptosis by protein kinase Cα, δ, ε and ζ: Evidence in yeast for transcription-dependent and -independent p53 apoptotic mechanisms
- 5 March 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (6) , 2141-2146
Aspartic vinyl sulfones: Inhibitors of a caspase-3-dependent pathway
- 5 March 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (6) , 2141-2146
Aspartic vinyl sulfones: Inhibitors of a caspase-3-dependent pathway
- 17 October 2009
- Published by Wiley in FEBS Letters
- Vol. 583 (22) , 3582-3588
Differential regulation of p53 function by protein kinase C isoforms revealed by a yeast cell system
The complexity of the mammalian p53 pathway and protein kinase C (PKC) family has hampered the discrimination of the effect of PKC isoforms on p53 activity. Using yeasts co‐expressing the human wild‐type p53 and a mammalian PKC‐α, ‐δ, ‐ε or ‐ζ, we showed a differential regulation of p53 activity and phosphorylation state by PKC isoforms. Whereas PKC‐α reduced the p53‐induced yeast growth inhibition and cell cycle arrest, PKC‐δ and ‐ε enhanced the p53 activity through p53 phosphorylation, and PKC‐ζ had no effect on p53. This work identified positive and negative p53 regulators which represent promising pharmacological targets in anti‐cancer therapy.
- 17 October 2009
- Published by Wiley in FEBS Letters
- Vol. 583 (22) , 3582-3588
Differential regulation of p53 function by protein kinase C isoforms revealed by a yeast cell system
The complexity of the mammalian p53 pathway and protein kinase C (PKC) family has hampered the discrimination of the effect of PKC isoforms on p53 activity. Using yeasts co‐expressing the human wild‐type p53 and a mammalian PKC‐α, ‐δ, ‐ε or ‐ζ, we showed a differential regulation of p53 activity and phosphorylation state by PKC isoforms. Whereas PKC‐α reduced the p53‐induced yeast growth inhibition and cell cycle arrest, PKC‐δ and ‐ε enhanced the p53 activity through p53 phosphorylation, and PKC‐ζ had no effect on p53. This work identified positive and negative p53 regulators which represent promising pharmacological targets in anti‐cancer therapy.